304 studies found for:    biogen | biogen
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Terminated Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Intervention: Biological: Baminercept alfa (BG9924)
2 Recruiting A Study Evaluating the Effectiveness of Tecfidera™ (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
Conditions: Relapsing-Remitting Multiple Sclerosis;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate (DMF)
3 Completed Open-Label Safety Extension Study of Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Avonex)
4 Terminated BG9924 in Combination With Methotrexate Extension of Study 104RA203
Condition: Rheumatoid Arthritis
Intervention: Drug: BG9924
5 Recruiting Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Condition: Multiple Sclerosis
Interventions: Drug: BIIB033;   Other: Placebo;   Drug: Interferon Beta-1a
6 Not yet recruiting Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate (DMF)-Treated Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: BG00012 (Dimethyl Fumarate);   Drug: Acetylsalicylic acid;   Drug: ASA-Placebo
7 Not yet recruiting A Phase 3b Study of BG00012's Effect on Vaccination Response in Subjects With Relapsed Forms of Multiple Sclerosis
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Drug: BG00012 (Dimethyl Fumarate);   Biological: Td (tetanus diphtheria toxoids);   Biological: Pneumococcal Vaccine;   Biological: KLH (Keyhole limpet hemocyanin)
8 Recruiting BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Subjects With Painful Lumbar Radiculopathy
Conditions: Painful Lumbar Radiculopathy;   Sciatica;   Radiculopathy
Interventions: Drug: BG00010;   Drug: Placebo
9 Recruiting Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect
Condition: Healthy
Interventions: Drug: BIIB061;   Drug: Placebo;   Drug: 14C-BIIB061
10 Completed Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo;   Biological: baminercept alfa;   Biological: Baminercept alfa
11 Completed ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Condition: Multiple Sclerosis
Intervention:
12 Recruiting 215ON201 BIIB033 In Acute Optic Neuritis (AON)
Condition: Acute Optic Neuritis
Intervention: Biological: BIIB033
13 Recruiting Anti-Tweak in Lupus Nephritis Patients
Condition: Lupus Nephritis
Interventions: Biological: BIIB023;   Biological: Placebo
14 Completed
Has Results
Natalizumab High Titer Immunogenicity and Safety
Condition: Multiple Sclerosis
Intervention: Drug: natalizumab
15 Completed A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Procedure: Plasma exchange;   Drug: natalizumab treatment
16 Recruiting BIIB017 Related Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: Peginterferon beta-1a;   Drug: naproxen
17 Recruiting A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Remittent Progressive;   Multiple Sclerosis, Primary Progressive;   Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: fampridine (BIIB041)
18 Recruiting Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010
Conditions: Painful Lumbar Radiculopathy;   Healthy
Interventions: Biological: BG00010;   Drug: Placebo
19 Recruiting An Efficacy and Safety Study of BG00012 in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: BG00012
20 Completed Open-Label Natalizumab Safety Extension Study
Condition: Multiple Sclerosis
Intervention: Drug: Natalizumab

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years